<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), with special attention to differences according to NHL subtype </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: From October 1986 to December 2002, 2,381 patients (median age, 9.37 years; range, 0.2 to 23.8 years; female-to-male ratio, 1:2.7) from Germany, Austria, and Switzerland were registered </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 2,086 patients were eligible for the consecutive multicenter protocols NHL-Berlin-Frankfurt-MÃ¼nster [BFM] -86, NHL-BFM-90, and NHL-BFM-95, and could be evaluated for outcome </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL </plain></SENT>
<SENT sid="4" pm="."><plain>The percentage of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-positive patients was 8.8% for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>), 5.4% for precursor B-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (pB-LBL), 3.3% for anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 0% for primary mediastinal large B-cell NHL (P &lt; .001) </plain></SENT>
<SENT sid="5" pm="."><plain>Most <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-positive patients with pB-LBL, T-LBL, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> had meningeal disease </plain></SENT>
<SENT sid="6" pm="."><plain>The probability of event-free survival (pEFS; +/- SE) at 5 years was 85% +/- 1% for the 2,086 protocol patients (median follow-up, 6.5 years; range, 0.3 to 17.7 years) </plain></SENT>
<SENT sid="7" pm="."><plain>For the 112 CNS-positive patients, pEFS was 64% +/- 5%, compared with 86% +/- 1% for the 1,927 CNS-negative patients (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>Although <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease had no impact on pEFS for advanced-stage T-LBL patients, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-positive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> had a worse average outcome than <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>-negative patients with stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> (60% +/- 5% v 81% +/- 3%; P &lt; .001) </plain></SENT>
<SENT sid="9" pm="."><plain>In multivariate analysis, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease was the strongest predictor for relapse in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients with advanced-stage disease </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Six percent of childhood/adolescent NHL patients were <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> positive </plain></SENT>
<SENT sid="11" pm="."><plain>However, the prevalence, pattern, and prognostic impact of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement differed among NHL subtypes </plain></SENT>
</text></document>